MARKETS
Markets

Summit Therapeutics Announced Opening Of Global Phase II SMT112-216 Trial Of Ivonescimab Alone Or Combined With Cadonilimab Or Ipilimumab In Previously Untreated Advanced Clear Cell Renal Cell Carcinoma,

Oct 19, 2026 · 07:07 AM ET· updated 1h ago

Share
Why It Matters

Summit Therapeutics started a big worldwide test of a new cancer medicine. Watching how the test goes tells you if the company's drug might work.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.